15 results on '"Boucher, C"'
Search Results
2. Evaluation of Safety and Efficacy of 3TC (Lamivudine) in Patients with Asymptomatic or Mildly Symptomatic Human Immunodeficiency Virus Infection: A Phase I/II Study
3. Zidovudine and Interferon- Combination Therapy versus Zidovudine Monotherapy in Subjects with Symptomatic Human Immunodeficiency Virus Type 1 Infection
4. Alternating Nevirapine and Zidovudine Treatment of Human Immunodeficiency Virus Type 1-Infected Persons Does Not Prolong Nevirapine Activity
5. Ordered Appearance of Zidovudine Resistance Mutations during Treatment of 18 Human Immunodeficiency Virus-Positive Subjects
6. Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients.
7. Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection.
8. High-Dose Nevirapine in Previously Untreated Human Immunodeficiency Virus Type 1-Infected Persons Does Not Result in Sustained Suppression of Viral Replication.
9. Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection.
10. Regional Challenges in the Prevention of Human Immunodeficiency Virus Drug Resistance.
11. Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333.
12. Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333.
13. Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection.
14. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.
15. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.